Glucagon
- Generic Name
- Glucagon
- Brand Names
- Baqsimi, Glucagen, Gvoke, Ogluo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 16941-32-5
- Unique Ingredient Identifier
- 76LA80IG2G
- Background
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.
...
- Indication
Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.
- Associated Conditions
- Severe Hypoglycemia
- Associated Therapies
- -
Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise
- Conditions
- Interventions
- First Posted Date
- 2017-07-13
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT03217175
- Locations
- 🇺🇸
MGH Diabetes Research Center, Boston, Massachusetts, United States
Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- AdventHealth Translational Research Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03139305
- Locations
- 🇺🇸
Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States
Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT03091673
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
Feasibility Trial Testing the Bionic Pancreas With ZP4207
- Conditions
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 13
- Registration Number
- NCT02971228
- Locations
- 🇺🇸
MGH Diabetes Center, Boston, Massachusetts, United States
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT02937558
- Locations
- 🇺🇸
UCSF School of Medicine, Division of Pediatric Endocrinology, San Francisco, California, United States
🇺🇸Washington University, St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸UCLA Mattel Children's Hospital, Los Angeles, California, United States
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT02910518
- Locations
- 🇩🇪
Investigational Site Number 276001, Neuss, Germany
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Institut de Recherches Cliniques de Montreal
- Registration Number
- NCT02846857
To Determine Tolerability to Glucagon Infusion in Obese Subjects
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- AdventHealth Translational Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT02817659
- Locations
- 🇺🇸
Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States
Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2
- Conditions
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Institut de Recherches Cliniques de Montreal
- Target Recruit Count
- 11
- Registration Number
- NCT02798250
- Locations
- 🇨🇦
Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada
A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT02778113
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount-Royal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.